» Articles » PMID: 32190495

Medication-related Osteonecrosis of the Jaw: A Review

Overview
Journal Cureus
Date 2020 Mar 20
PMID 32190495
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a rare, severe debilitating condition from unknown causes. It is characterized by nonhealing exposed bone in a patient with a history of antiresorptive or antiangiogenic agents in the absence of radiation exposure to the head and neck region. The first case of MRONJ was reported in the early 2000s. Diagnostic criteria for MRONJ was developed by the American Association of Oral and Maxillofacial Surgeons (AAOMS) based on pharmacological history as well as clinical and radiographic features. Antiresorptive medications such as bisphosphonate and denosumab are currently considered the treatment of choice in patients with osteoclastic bone disease. These reduce bone turnover and improve bone density, thereby improving bone quality. These agents have also been shown to reduce the risk of osteoporotic fractures due to their potent effect in suppressing osteoclastic activity by slowing the remodeling process and increasing bone density, thereby improving quality of life for most of the patients. Despite the great benefits of bisphosphonates and other antiresorptive medications, osteonecrosis of the jaw (ONJ) due to the effects of these medications in the presence of a local risk factor is a significant drawback. Moreover, antiangiogenic drugs play a major role in developing bone necrosis. They are prescribed in cancer cases to prevent metastasis through the blood and lymph nodes. These drugs interfere with the formation of new blood vessels, resulting in ischemia and eventually ONJ. This risk can be managed by evaluating the route and the duration of administration as such a risk can be considered dose-time dependent. As a preventive measure, dental screening before initiating any type of ONJ-related medications can significantly lower the risk of ONJ. Treatment goals can be achieved through pain and infection control, in addition to the management of bone necrosis and resorption. The aim of this review is to identify all causative agents and summarize the preventive measures, diagnostic criteria, and treatment strategies related to MRONJ.

Citing Articles

Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol.

Slowik L, Toton E, Nowak A, Wysocka-Slowik A, Okla M, Slebioda Z J Clin Med. 2025; 14(3).

PMID: 39941644 PMC: 11818125. DOI: 10.3390/jcm14030974.


Management of Medication-Related Osteonecrosis of the Jaws With Hyperbaric Oxygen Therapy: A Case Report.

Anand R, Kumar Y, Bhagat N, Chakarvarty K, Jaiswal Y Cureus. 2024; 16(10):e70940.

PMID: 39502998 PMC: 11537256. DOI: 10.7759/cureus.70940.


Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series.

Frutuoso F, Freitas F, Vilares M, Francisco H, Marques D, Carames J Diseases. 2024; 12(9).

PMID: 39329874 PMC: 11431443. DOI: 10.3390/diseases12090205.


Piezoelectric Surgery, Er:YAG Laser Surgery and Nd:YAG Laser Photobiomodulation: A Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws (MRONJ).

Vescovi P, De Francesco P, Giovannacci I, Leao J, Barone A Dent J (Basel). 2024; 12(8).

PMID: 39195105 PMC: 11353968. DOI: 10.3390/dj12080261.


Prediction of wound healing status following dental extraction using Adapted-University of Connecticut osteonecrosis numerical scale: A retrospective study.

Suryani I, Shujaat S, That M, Coucke W, Jacobs R Health Sci Rep. 2024; 7(6):e2184.

PMID: 38915354 PMC: 11194833. DOI: 10.1002/hsr2.2184.


References
1.
Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

2.
Akashi M, Kusumoto J, Takeda D, Shigeta T, Hasegawa T, Komori T . A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw. Oral Maxillofac Surg. 2018; 22(4):369-378. DOI: 10.1007/s10006-018-0732-8. View

3.
Peer A, Khamaisi M . Diabetes as a risk factor for medication-related osteonecrosis of the jaw. J Dent Res. 2014; 94(2):252-60. PMC: 4438733. DOI: 10.1177/0022034514560768. View

4.
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G . Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent. 2016; 6(2):97-104. PMC: 4820581. DOI: 10.4103/2231-0762.178742. View

5.
Shibahara T . Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Tohoku J Exp Med. 2019; 247(2):75-86. DOI: 10.1620/tjem.247.75. View